BMSSC
APGE

B. Metzler seel. Sohn & Co’s Apogee Therapeutics APGE Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Hold
11,693
– – 0.01% 480
2026
Q1 		$984K Buy
+11,693
New +$849K 0.01% 550

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

B. Metzler seel. Sohn & Co's APGE Position: Q2 2026 in Review

B. Metzler seel. Sohn & Co held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 11,693 shares worth $1.55M. The position accounts for 0.01% of the portfolio, ranked #480.

B. Metzler seel. Sohn & Co first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • B. Metzler seel. Sohn & Co held 11,693 shares of Apogee Therapeutics worth $1.55M as of Q2 2026.
  • B. Metzler seel. Sohn & Co left its Apogee Therapeutics share count unchanged in Q2 2026.
  • Apogee Therapeutics made up 0.01% of B. Metzler seel. Sohn & Co's portfolio in Q2 2026, its #480 holding.
  • B. Metzler seel. Sohn & Co first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2026, filed 11 Aug 2026.